The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy
Open Access
- 15 November 2023
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (4)
Abstract
Germline pathogenic variants in the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway are the molecular cause of RASopathies, a group of clinically overlapping genetic syndromes. RASopathies constitute a wide clinical spectrum characterized by distinct facial features, short stature, predisposition to cancer, and variable anomalies in nearly all the major body systems. With increasing global recognition of these conditions, the 8th International RASopathies Symposium spotlighted global perspectives on clinical care and research, including strategies for building international collaborations and developing diverse patient cohorts in anticipation of interventional trials. This biannual meeting, organized by RASopathies Network, was held in a hybrid virtual/in‐person format. The agenda featured emerging discoveries and case findings as well as progress in preclinical and therapeutic pipelines. Stakeholders including basic scientists, clinician‐scientists, practitioners, industry representatives, patients, and family advocates gathered to discuss cutting edge science, recognize current gaps in knowledge, and hear from people with RASopathies about the experience of daily living. Presentations by RASopathy self‐advocates and early‐stage investigators were featured throughout the program to encourage a sustainable, diverse, long‐term research and advocacy partnership focused on improving health and bringing treatments to people with RASopathies.Keywords
Funding Information
- BioMarin Pharmaceutical
- Boehringer Ingelheim
- Children's Hospital Colorado
- National Cancer Institute
- National Center for Advancing Translational Sciences (R13TR004509)
- Revolution Medicines
- Children's Tumor Foundation (2018‐01‐005)
- National Institutes of Health (R00CA245122)
- Deutsche Forschungsgemeinschaft (Ci216/2‐1)
- National Heart, Lung, and Blood Institute (R35 HL135742)
- National Institute of Neurological Disorders and Stroke (K08‐NS128272)
This publication has 14 references indexed in Scilit:
- Increased osteoclastogenesis contributes to bone loss in the Costello syndrome Hras G12V mouse modelFrontiers in Cell and Developmental Biology, 2022
- Cognitive Phenotype and Psychopathology in Noonan Syndrome Spectrum Disorders through Various Ras/MAPK Pathway Associated Gene VariantsJournal of Clinical Medicine, 2022
- HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome modelsJournal of Clinical Investigation, 2022
- Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndromeiScience, 2021
- MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disordersMolecular Autism, 2021
- Impaired instrumental learning in Spred1−/− mice, a model for a rare RASopathyGenes, Brain and Behavior, 2021
- Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-InhibitionJACC, 2019
- Noonan syndrome in diverse populationsAmerican Journal of Medical Genetics Part A, 2017
- Evidence-Based Social Skills Training for Adolescents with Autism Spectrum Disorders: The UCLA PEERS ProgramJournal of Autism and Developmental Disorders, 2011
- The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulationCurrent Opinion in Genetics & Development, 2009